Explore
For Enterprise
Join for Free
Log In

艺术与人文
商务
计算机科学
数据科学
信息技术
健康
数学和逻辑
个人发展
物理科学与工程
社会科学
语言学习
學位和證書

瀏覽 Coursera 的全部課程

瀏覽
搜索
企業版
登錄
免費加入

Recovery and purification of large molecules

Loading...

Industrial Biotechnology

曼彻斯特大学

4.7（251 個評分） | 11K 名學生已註冊

查看授課大綱

Fossil fuels have been the primary energy source for society since the Industrial Revolution. They provide the raw material for the manufacture of many everyday products that we take for granted, including pharmaceuticals, food and drink, materials, plastics and personal care. As the 21st century progresses we need solutions for the manufacture of chemicals that are smarter, more predictable and more sustainable. Industrial biotechnology is changing how we manufacture chemicals and materials, as well as providing us with a source of renewable energy. It is at the core of sustainable manufacturing processes and an attractive alternative to traditional manufacturing technologies to commercially advance and transform priority industrial sectors yielding more and more viable solutions for our environment in the form of new chemicals, new materials and bioenergy. This course will cover the key enabling technologies that underpin biotechnology research including enzyme discovery and engineering, systems and synthetic biology and biochemical and process engineering. Much of this material will be delivered through lectures to ensure that you have a solid foundation in these key areas. We will also consider the wider issues involved in sustainable manufacturing including responsible research innovation and bioethics. In the second part of the course we will look at how these technologies translate into real world applications which benefit society and impact our everyday lives. This will include input from our industry stakeholders and collaborators working in the pharmaceutical, chemicals and biofuels industries. By the end of this course you will be able to: 1. Understand enzymatic function and catalysis. 2. Explain the technologies and methodologies underpinning systems and synthetic biology. 3. Explain the diversity of synthetic biology application and discuss the different ethical and regulatory/governance challenges involved in this research. 4. Understand the principles and role of bioprocessing and biochemical engineering in industrial biotechnology. 5. Have an informed discussion of the key enabling technologies underpinning research in industrial biotechnology 6. Give examples of industrial biotechnology products and processes and their application in healthcare, agriculture, fine chemicals, energy and the environment.

審閱

4.7（251 個評分）

5 stars
179 ratings
4 stars
59 ratings
3 stars
12 ratings
2 stars
1 ratings

JN

May 21, 2018

The lectures were divided into modules that were appropriate in length/tie. Speakers were very easy to comprehend and the outline of the topics were well presented.

KM

Nov 16, 2017

Hi, i am taking this online course via coursera i would like to know if their is a certificate of recognition for the course?

從本節課中

Biochemical and Bioprocess Engineering

Biochemical and bioprocess engineering is concerned with the design of processes which involve biological transformations to manufacture a range of bio-based chemicals, biopharmaceuticals and biofuels. Through applying knowledge of process constraints, which are usually described mathematically, biochemical engineers are able to design a series of integrated process steps or “unit operations” which together make up a bioprocess. This module will give an appreciation of the key role biochemical engineering has in translating discoveries coming from life sciences and synthetic biology, such as improved microbial platforms for product expression, into economically viable full scale production processes. Key engineering concepts and the problem solving approach required for the design of bioprocesses will be taught by a group of biochemical engineers from The University of Manchester, University College London and Technical University of Denmark.

Introduction to Biochemical and Bioprocess Engineering12:51

Microbial fermentation processes and bioreactor design10:12

Biocatalysis and enzymatic processes24:52

Recovery and purification of small molecules11:42

Recovery and purification of large molecules9:31

Process economics and scale-up19:18

教學方

Prof. Nicholas Turner
Deputy Director
Prof. Nigel Scrutton
Director

Hello, my name is James Lawrence from the Department of Biomedical Engineering at

UCL, and I'll be talking you through this video on recovery and

purification of large molecules.

So in the last video, we discussed the fact that all of the products

derived from biological processes will need to be recovered and

purified before they can be sold or used in manufacture of a different product.

The design of the process that we used to do this the recovery and

purification will depend on the type of product, product location and

the nature of the contaminants present.

As a reminder for the purpose of this course, we have broken down the type of

product into two categories, small molecules and large molecules.

When we use the term large molecules,

we mean molecules with a high molecular weight.

For example therapeutic proteins, monoclonal antibodies or enzymes.

The production of large molecules will be done almost exclusively by living cells,

since the assembly of these molecules requires processes that could

not be carried out by individual enzymes or even a series of enzymatic steps.

The design of the process by which we recover a large amount of products is

therefore going to be affected primarily by the location of the product

within the cell, i.e.

whether it is made inside the cell, it's an intercellular product, or whether it is

going to be secreted out of the cell, so it's an extracellular product.

And that, in turn, is going to be defined by the type of cell producing it and

the size of the molecule itself.

As an additional complication,

a loss of these molecular problems tend to be biopharmaceuticals,

meaning that the products need to be purified sufficiently, so that they could

be administered to a patient without causing harm to the patient.

Usually this means purity in excess of 99.95%, and

this is a legal requirement that must be required for any pharmaceutical.

If we have an intracellular product, as would be the case if we had for

example an E.coli cell making a large molecule like an antibody fragment,

then we would need to recover the cells and homogenize them to get out

our product out, as we described in the previous video.

If we had an extracellular product, we would not require any homogenization ,

simply the removal of the cells from our products

using a standard solid- liquid separation method,

such as filtration or centrifugation, also described in the last video.

The last process that we go through is most likely to be used because

it typically has lower cost associated with it and

is capable of having higher throughputs.

The choice of cell type in our process is often influenced by the complexity

of the product, and how easy it's going to be to subsequently purify it.

So for example in mammalian cell lines such as a Chinese hamster ovary cells,

we'll typically be able to secrete a large product that a microbial cell would have

to keep intracellularly as it couldn't express that through a cell membrane.

This means that using Chinese hamster ovary cells to produce a large molecular

product will reduce the number of steps that we're required to purified.

However, there's going to be a tradeoff, because as a rule of thumb,

the simpler the cell type we use, the higher the cell mass we can achieve, and

therefore the more product we are able to make overall.

A potential extra step in the purification process for large molecules would only

occur in the specific case of a bacterial cell overproducing our molecule of choice.

This overproduction would lead to misfolding and

aggregation of the proteins within the cells, creating

what are called inclusion bodies, which are small particles of misfolded proteins,

large particular proteins which tend to be about half a micron in size.

They are small robust particles, which are very hard to break apart.

So they are actually relatively easy to separate from the cells and

other contaminants present.

We do this by breaking the cells and the resulting cell debris into tiny pieces,

and then centrifuging as the resulting suspension to separate out the more dense

inclusion bodies from the very fine broken down debris and other contaminants.

After the inclusion bodies have been separated out, but

before any further purification can occur, the bodies must be separated out into

individual molecules by the addition of a chaotrope.

There's a chemical that is used to unfold proteins.

The advantage of making inclusion bodies is that you can often get

more products per cell.

And actually it simplifies the further purification steps, provided that you can

actually unfold and refold your products back into its natural active form.

So, having extracted our products from our cells, if that's necessary,

our next step would probably be chromatography.

So chromatography involves the passing of liquids, known as the mobile phase,

through columns of packed with, porous beads, which are known as the stationary phase.

In doing so, we can use the beades to effect a separation of the molecules

passing between them in the liquid,

on the basis either of the size of our molecules, the charge on our molecules,

the hydrophobicity or their affinity for a particular ligand.

Chromatography units can be operated in one of two modes to effect

the purification.

The first is 'bind and elute', where we bind the products within the column,

let everything else flow through, and then release the products again,

leaving it as a pure stream on its own.

And the second mode is a flow-through, where we bind specific impurities

within our product stream and let the product flow through itself.

So size exclusion chromatography,

as the name suggests, separates our molecules out based on their size.

The smaller molecules are absorbed into the pores of the beads in the stationary

phase and have to move through these beads, whilst the larger molecules can

move only through the gaps between the beads and column.

This means that the smaller molecules have to travel through the column

much more slowly.

They are inhibited by the fact that they have to travel through these

small pores within the beads themselves, and they will actually come

out of the column known as eluting, later on than larger molecules.

So there's no attraction to the beads themselves, there's no attraction between

either contaminants or products in the stationary phase.

This type of chromatography is always operated in flow through mode.

Ion-exchange chromatography separates based on charge,

which could be positive or negative charge known as anion or cation respectively.

Put another way,

cation-exchange chromatography retains positively charged molecules,

because the stationary phase has a negatively charged,

functional group, on its surface.

Conversely, anion-exchange chromatography, retains negatively charged molecules,

using positively charged,

functional groups on the surface of the stationary phase.

So, if we were using cation-exchange, in our process, and

our product was positively charged, we would be operating a

'bind and elite' mode, as we would be capturing our products on the column,

whilst our contaminants would be allowed to flow through.

If the product was negatively charged, we would be operating in flow through mode.

As the product would be repelled by negatively charged stationary phase,

whilst any positively charged contaminants would be captured by the column.

The opposite would be true if we were using anion exchange instead.

Finally, the other two types of chromatography, hydrophobic interaction

chromatography and affinity chromatography both work in quite similar manner.

In this case, the stationary phase is designed specifically to bind

molecules based on either hydrophobicity or the affinity of molecule for

a specific ligand, which should be held on the stationary phase.

These types of columns tend to be used as the final steps in our purification

process,

As they allow the capture of very specific molecules, so

can reach very high purities, but they also tend to be very expensive.

So we generally want to remove as much of the contaminating material as possible

before we get to one of these steps.

So, lastly just presenting an overview of all of the recovery and

purification methods that we've covered in detail in the last two videos, and

the different properties by which they exploit to effect a separation.

You noticed, that we haven't included homogenization in this list,

as it's not really a separation step, but instead a pre-treatment step,

used to break open cells and access intacellular products.

As a final note, it's worth mentioning that, if the large molecular product

was made by a mammalian cell line, then there would need to be both a viral inactivation and

a viral filtration step within the purification chamber after any chromatography steps.

Again, this would be a legal requirement to ensure that any pharmaceutical products

we made using ourselves, will be safe for use for humans, or indeed, for animals.

探索我們的目錄

免費加入並獲得個性化推薦、更新和優惠。

Coursera 致力於普及全世界最好的教育，它與全球一流大學和機構合作提供在線課程。

© 2019 Coursera Inc. 保留所有權利。

通過 App Store 下載

通過 Google Play 獲取

Coursera
關於
管理團隊
工作機會
目錄
證書
MasterTrack™ 證書
學位
企業版
政府版

社區
Learners
Partners
Developers
Beta Testers
Translators

連接
博客
Facebook
領英
Twitter
Instagram
YouTube
技術博客

更多
條款
隱私
幫助
內容訪問
媒體
聯繫我們
目錄
附屬公司